About Corsair Pharma
Corsair Pharma, Inc. is a development stage biotechnology company operating as a portfolio company of Velocity Pharmaceutical Development, LLC and is focused on the development of novel prodrugs of treprostinil to treat patients with PAH using a once-daily transdermal patch.
CEO: David Collier
3 articles with Corsair Pharma
Corsair Pharma, Inc. today announced it will present at the LifeSci Partners Private Company Summer Symposium , to be held virtually July 21-23, 2021.
Corsair Pharma, Inc. today announced it will host a Key Opinion Leader (KOL) webinar to discuss the current treatment landscape for Pulmonary Arterial Hypertension (PAH) on Thursday, July 8 th , at 10:30 a.m. ET.
Corsair Pharma and United Therapeutics Enter Into Strategic Collaboration to Advance Novel Treprostinil Prodrugs
Under the terms of the license agreement, United Therapeutics has been granted an exclusive license to Corsair's intellectual property for the development of treprostinil prodrug formulations.